Weight gain in breast cancer patients: Tamoxifen versus anastrazole

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10544-10544
Author(s):  
P. McGowan ◽  
M. C. Perry ◽  
J. E. Hewett ◽  
B. Ge ◽  
K. Sanfilippo
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Significant Weight Gain ◽  
Estrogen Receptor Modulators ◽  
Significant Difference ◽  
Group A

10544 Background: Weight gain is a common complaint among breast cancer patients, especially those taking tamoxifen. Aromatase inhibitors have been increasingly used in postmenopausal breast cancer patients, and are generally thought to have a more tolerable side-effect profile than selective estrogen receptor modulators (SERM’s). This study specifically addresses weight gain in patients on the SERM, tamoxifen, compared to patients on the aromatase inhibitor, anastrazole. Methods: Ninety-six outpatients with primary breast cancer of any stage received standard doses of adjuvant hormonal therapy. Seventy received tamoxifen (Group T) and 26 anastrazole (Group A). The nursing staff in the clinic weighed all patients at the time of diagnosis, at start of chemotherapy (if received), at start of hormone therapy, and at 3 month intervals for 12 months after starting hormone therapy. Data were gathered in a retrospective manner. Results: Demographic variables were compared between the two groups. In all patients, it was noted that increasing age was correlated with greater weight gain at 3 months after starting hormone therapy (p = 0.0257), but not at any other intervals. No other variables were significantly correlated with weight gain. In Group T, mean weight gain was clinically (>1.8 kgs) and statistically significant at 9 and 12 months (p = 0.0137, p = 0.0003). In Group A, mean weight gain was not clinically significant at any point. Using the Wilcoxon two-sample tests to compare groups T and A, it was shown that there was no statistically significant difference in weight gain between the two groups at any interval (see table). Conclusions: These results are consistent with previous studies that show significant weight gain in breast cancer patients on tamoxifen. This study failed to show a statistically significant difference in weight gain between patients on tamoxifen and patients on anastrazole. Group A did not have statistically significant weight gain at any interval after starting hormone therapy. [Table: see text] No significant financial relationships to disclose.

scholarly journals Evaluation of Pentosidine as Bone Quality Marker in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

2020 ◽  
Author(s):  
Hideo Shigematsu ◽  
Tomoyuki Yoshiyama ◽  
Daisuke Yasui ◽  
Shinji Ozaki
Keyword(s):  
Breast Cancer ◽  
Bone Turnover ◽  
Cancer Patients ◽  
Bone Quality ◽  
Bone Turnover Markers ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Average Change ◽  
Turnover Markers

Abstract Background: Osteoporosis and fractures are important aromatase inhibitor (AI) related adverse events in postmenopausal women with hormone receptor positive breast cancer. An increment of pentosidine is associated with a deterioration of bone quality. In this study, pentosidine was evaluated in postmenopausal breast cancer patients receiving AIs. Methods: Fifty postmenopausal breast cancer patients receiving AIs were retrospectively evaluated. Sixteen patients were given a bone modifying agent (BMA) concomitant with AIs. Changes of pentosidine, bone turnover markers and bone mineral density (BMD) before and after 12 months of AI therapy were compared between BMA administered patients (BMA group) and a non-BMA group.Results: There was no significant difference between pentosidine low and high groups in regard to age, height, weight, BMD of femoral neck and lumbar spine, and bone turnover markers including TRACP-5b and BAP. In the non-BMA group, pentosidine was increased in 18 cases (53%), and the average change of pentosidine was 21.5% (95%CI; 0.23 to 42.7%, p=0.048). In the BMA group, pentosidine was increased in 2 two cases (13%), and the average change of pentosidine was -16.6% (95%CI; -30.6 to -2.6%, p=0.023). There was a significantly lower proportion of pentosidine-increased cases (p=0.0065) and decrease of pentosidine (p=0.021) in the BMA group compared to those in the non-BMA group. Conclusions: Pentosidine was an independent factor from risk factors of osteoporotic fracture. Pentosidine was increased with AI, however, BMA inhibits an AI-induced increase of pentosidine in postmenopausal breast cancer patients.

Breast cancer and vitamin D in postmenopausal minorities.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 17-17
Author(s):  
Demet Gokalp Yasar ◽  
Pam Khosla
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Bone Health ◽  
Postmenopausal Breast Cancer ◽  
Cancer Information ◽  
Minority Population ◽  
Breast Cancer Patients ◽  
Significant Difference

17 Background: Bone health is a particular concern for breast cancer survivors, because these women have 15% higher fracture risk than women without a history of breast cancer. Many studies have suggested that vitamin D deficiency may be involved in breast cancer initiation, progression, and prognosis. This study examines the prevalence of vitamin D deficiency among postmenopausal breast cancer patients in minority population. Methods: This retrospective study reviewed the electronic records of 200 postmenopausal breast cancer patients from ethnic groups of blacks, Hispanics and Asians. Results: Of the 200 patients, 84 (42%) had their 25-OHD levels checked at least once. Of patients, 42.7% found body mass index (BMI)>30kg/m2. There was significant difference between race and BMI (p<0.05). Black Vitamin D deficiency (level< 20ng/mL) found in 35 (41.7%), vitamin D insufficiency (level range 20-30ng/mL) found in 30 (35.7%) of the patients. The median serum 25-OHD level was 21 (range 4-65ng/ml). The serum 25-OHD levels did not have significant difference among blacks and Hispanics. Tumor stages found negatively correlated with 25-OHD levels r=-0.227 and p=0.04. Conclusions: This study revealed that vitamin D deficiency has a high prevalence among postmenopausal breast cancer minority population. Data from Third National Health and Nutrition Examination survey showed that mean serum 25-OHD levels among white, Hispanic and black women were 76ng/ml, 56.7ng/ml and 45.3ng/ml, respectively. Also, prevalence rate of vitamin D deficiency is reported in the studies among breast cancer patients are approximately 30%. Our data compared with this general population’s numbers is low; our median 25-OHD level was 21ng/ml. Our study found negative correlation with Vitamin D levels and stages of the breast cancer. Information is lacking on direct prognostic effect of vitamin D in breast cancer but this findings including our study support the hypothesis that vitamin D has a role in the pathogenesis of breast cancer. In the setting of breast cancer diagnosis either for bone health, or for breast cancer prognosis in postmenopausal women, we advocate routine 25-OHD levels screening for the vitamin D deficiency especially in minority populations would be beneficial.

scholarly journals Combination of Endogenous Estradiol and Adipokine Leptin in Breast Cancer Risk and Prognosis Assessment in Postmenopausal Chinese Women

2021 ◽  
Vol 12 ◽  
Author(s):  
Yang Luo ◽  
Han-Bing Li ◽  
Yue Zhang ◽  
Yu-Xin Wu ◽  
Di Shen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Chinese Women ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Poor Prognostic Factor ◽  
Significant Difference

ObjectiveOur study aims to clarify the role of estradiol and leptin in breast cancer risk and prognostic assessment in postmenopausal Chinese women.DesignThe serum circulating estradiol and leptin level was detected by ELISA. Then the correlation between estradiol, leptin level, and clinical characteristics was analyzed using Fisher’s exact test. Next, the Kaplan-Meier model was used to analyze the association between estradiol, leptin, and prognosis of postmenopausal breast cancer patients in our cohort and the TCGA dataset.SettingThe study was conducted at the National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College.PatientsA total of 182 postmenopausal breast cancer patients and 111 healthy subjects from January 2010 to August 2010 were included in the analysis. Another 702 cases with breast cancer were retrieved from The Cancer Genome Atlas (TCGA) database for subsequent analysis.Main Outcome MeasureSerum circulating estradiol and leptin level.ResultsThe level of estradiol was significantly higher (P&lt;0.001) but the level of leptin had no significant difference (P = 0.764) in postmenopausal breast cancer patients compared with healthy subjects. The level of estradiol and leptin was not significantly different between estrogen receptor (ER) positive and ER-negative groups (P&gt;0.05). Estradiol was significantly correlated with tumor T stage (P = 0.002) and leptin was significantly associated with perineural invasion (P = 0.014). In addition, the disease-free survival of patients with a high level of estradiol was significantly shorter (P = 0.025) but leptin tended to be a protective factor for overall survival in TCGA analysis (P = 0.038).ConclusionCirculating estradiol and leptin played important roles in the risk of postmenopausal breast cancer even in low-estrogen nations with an independent expression of ER status. High circulating estradiol was a poor prognostic factor and leptin may be a protection signal in Chinese postmenopausal patients with breast cancer.

scholarly journals Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients

Breast Care ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Vanesa Quiroga-García ◽  
Beatriz Cirauqui-Cirauqui ◽  
Cristina Bugés-Sánchez ◽  
Miguel Ángel Luna-Tomás ◽  
Eva María Castellà-Fernández ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Elderly Women ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Time To Progression ◽  
Hormone Sensitive

Background: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer. However, no study has compared the efficacy of AIs alone versus AIs followed by surgery. Methods: 33 postmenopausal breast cancer patients were treated with primary hormone therapy. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor type 2 receptor (HER2) expression levels were analyzed by immunohistochemistry. After hormone therapy, eligible patients underwent surgery, and those who were not candidates for surgery continued on hormone therapy. We retrospectively analyzed time to progression, overall survival, response, and impact of surgery on outcome. Results: All patients were ER+. HER2 was successfully analyzed in 30 patients, all of whom were HER2-. The median time to progression was 94 months, and the median overall survival was not reached, while the mean overall survival was 123 months. The overall response rate was 63.6%, with 9.1% complete responses. No significant differences in time to progression or survival were observed between patients who underwent surgery and those who did not. Conclusions: Primary hormone therapy with AIs is effective in elderly breast cancer patients with high levels of hormone receptors and may provide a feasible and tolerable alternative to surgery in selected hormone-sensitive breast cancer patients.

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

scholarly journals Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients

2021 ◽  
Author(s):  
Shozo Ohsumi ◽  
Sachiko Kiyoto ◽  
Mina Takahashi ◽  
Seiki Takashima ◽  
Kenjiro Aogi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prospective Study ◽  
Cancer Patients ◽  
Scalp Cooling ◽  
Breast Cancer Patients ◽  
Chemotherapy Infusion ◽  
Group A ◽  
Neo Adjuvant Chemotherapy ◽  
Group B

Abstract Purpose Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We conducted a prospective study of hair recovery after chemotherapy with scalp cooling. Patients and methods One hundred and seventeen Japanese female breast cancer patients who completed planned (neo)adjuvant chemotherapy using the Paxman Scalp Cooling System for alopecia prevention were evaluated for alopecia prevention in our prospective study. We evaluated their hair recovery 1, 4, 7, 10, and 13 months after chemotherapy. Primary outcomes were grades of alopecia judged by two investigators (objective grades) and patients’ answers to the questionnaire regarding the use of a wig or hat (subjective grades). Results Of 117 patients, 75 completed scalp cooling during the planned chemotherapy cycles (Group A), but 42 discontinued it mostly after the first cycle (Group B). Objective and subjective grades were significantly better in Group A than in Group B throughout 1 year, and at 4 and 7 months after chemotherapy. When we restricted patients to those with objective Grade 3 (hair loss of > 50%) at 1 month, Group A exhibited slightly faster hair recovery based on the objective grades than Group B. There was less persistent alopecia in Group A than in Group B. Conclusions Scalp cooling during chemotherapy infusion for Japanese breast cancer patients increased the rate of hair recovery and had preventive effects against persistent alopecia.

scholarly journals The sexual lives of breast cancer patients: Coping with changes associated with treatment

2017 ◽  
Vol 6 (1) ◽  
pp. 61
Author(s):  
Ayumi Yoshikawa ◽  
Shinya Saito ◽  
Makiko Kondo ◽  
Yuko Tsuyumu ◽  
Naruto Taira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Sexual Activity ◽  
Cancer Patients ◽  
Sexual Life ◽  
Breast Cancer Patients ◽  
Coping Methods ◽  
Virtuous Cycle ◽  
Depth Interviews ◽  
Analyze Data

Objective: To clarify how breast cancer patients undergoing post-surgical hormone therapy cope with changes in their sexual lives and support themselves and their partners during these changes.Methods: Participants were 37 breast cancer patients undergoing post-surgical hormone therapy and attending mammary outpatient clinics. In-depth interviews and grounded theory were used to collect and analyze data, respectively.Results: First, sexual life was divided into four groups: “No complaint” regarding sexual activity, “Slight discord”, “Handicapped in meeting a life partner” and “Uninterested” in sexual activity. Sexual life during surgical-hormone therapy did not change significantly from sexual life before breast cancer. Second, meanings of sexual activity for breast cancer patients were divided into five, “Regaining femininity”, “Confirming love”, “Sharing pleasure”, “Response to partner’s higher desire” and “Procreation”. They differed by group. Third, coping strategies were divided into six, “Virtuous cycle to confirm love and regain lost femininity”, “Struggle to avoid relationship crisis”, “Reconfirmation of partner’s affection by his abstinence”, “Attempt to recover the sexual activity they hope for”, “Pursuing children or assuaging partner’s desire by other means” and “Difficulty making a partner continue to have sexual activity”.Conclusions: Nurses should screen breast cancer patients for changes in their sexual lives and to ascertain what sexual activity means to patients, and support them in selecting appropriate coping methods.

Sign in / Sign up

Export Citation Format

Share Document